On June 17, 2025, Wolfe Research initiated coverage on Avidity Biosciences (RNA, Financial), providing investors with new insights into the biotechnology company. The esteemed analyst Andy Chen from Wolfe Research has assigned an 'Outperform' rating to the stock, marking a significant milestone for the company.
In conjunction with this newly initiated coverage, Wolfe Research has announced a price target for Avidity Biosciences (RNA, Financial) at $55.00 USD. This marks an important data point for investors as they consider potential gains from holding the stock.
The decision by Wolfe Research and analyst Andy Chen to commence coverage with an 'Outperform' rating reflects their confidence in the future prospects of Avidity Biosciences (RNA, Financial). Investors and market participants will be keen to observe how the stock performs in the coming months, especially in light of this new analyst attention.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Avidity Biosciences Inc (RNA, Financial) is $68.53 with a high estimate of $96.00 and a low estimate of $54.00. The average target implies an upside of 123.02% from the current price of $30.73. More detailed estimate data can be found on the Avidity Biosciences Inc (RNA) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Avidity Biosciences Inc's (RNA, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Avidity Biosciences Inc (RNA, Financial) in one year is $6.88, suggesting a downside of 77.61% from the current price of $30.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Avidity Biosciences Inc (RNA) Summary page.
